866-997-4948(US-Canada Toll Free)

Diabetic Neuropathy - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 117 Pages

Diabetic Neuropathy - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy Pipeline Review, H2 2016, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape.

Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning and pain. The predisposing factors are obesity, hypertension, high lipid and sugar levels, smoking, etc. It may be managed by medication and dietary modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Neuropathy Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 1, 1, 16 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.Diabetic Neuropathy.

Diabetic Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diabetic Neuropathy Overview 9
Therapeutics Development 10
Pipeline Products for Diabetic Neuropathy - Overview 10
Pipeline Products for Diabetic Neuropathy - Comparative Analysis 11
Diabetic Neuropathy - Therapeutics under Development by Companies 12
Diabetic Neuropathy - Therapeutics under Investigation by Universities/Institutes 14
Diabetic Neuropathy - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Diabetic Neuropathy - Products under Development by Companies 18
Diabetic Neuropathy - Products under Investigation by Universities/Institutes 20
Diabetic Neuropathy - Companies Involved in Therapeutics Development 21
Achelios Therapeutics, Inc. 21
Araim Pharmaceuticals, Inc. 22
Celgene Corporation 23
Commence Bio, Inc. 24
Glucox Biotech AB 25
KPI Therapeutics, Inc. 26
Lpath, Inc. 27
Medifron DBT Co., Ltd. 28
Neuralstem, Inc. 29
NovaLead Pharma Pvt. Ltd. 30
Novartis AG 31
Omeros Corporation 32
PhiloGene, Inc. 33
Reata Pharmaceuticals, Inc. 34
Relief Therapeutics S.A. 35
Sucampo Pharmaceuticals, Inc. 36
ViroMed Co Ltd 37
Diabetic Neuropathy - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Target 39
Assessment by Mechanism of Action 42
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
atexakin alfa - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
benfotiamine - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
BNV-222 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
cibinetide - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
CMB-200 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Cyndacel-M - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
EMA-401 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
ketoprofen - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Lpathomab - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
MDR-652 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
ND-07 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
NLP-198 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
NSI-189 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
NSI-566 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
OMS-721 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
PDA-002 - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
pirenzepine hydrochloride - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
RTA-901 - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
RTU-1096 - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
Small Molecule for Pain - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
Small Molecules for Diabetic Neuropathy - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
Small Molecules to Inhibit Hsp90 for Amyotrophic Lateral Sclerosis and Peripheral Neuropathy - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
U-2902 - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
VM-202 - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
XK-568b - Drug Profile 105
Product Description 105
Mechanism Of Action 105
R&D Progress 105
Diabetic Neuropathy - Dormant Projects 106
Diabetic Neuropathy - Discontinued Products 110
Diabetic Neuropathy - Product Development Milestones 111
Featured News & Press Releases 111
Sep 08, 2016: ViroMed proceeding with the Worlds first phase III gene therapy clinical trial for diabetic peripheral neuropathy 111
Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy 111
Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition 112
Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab 114
Sep 12, 2011: Spinifex Pharmaceuticals Presents New Data On EMA401 In Model Of Diabetic Neuropathy At 21st Annual NEURODIAB Meeting 114
Mar 18, 2011: ViroMed Enrolls Final Patient For US VM202-DPN Phase I/II Clinical Trial 115
Mar 04, 2009: ViroMed Receives Approval from US FDA for Phase I/II Trial for Diabetic Neuropathy 115
Appendix 116
Methodology 116
Coverage 116
Secondary Research 116
Primary Research 116
Expert Panel Validation 116
Contact Us 116
Disclaimer 117

List of Tables
Number of Products under Development for Diabetic Neuropathy, H2 2016 10
Number of Products under Development for Diabetic Neuropathy - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Development by Companies, H2 2016 (Contd..1) 19
Products under Investigation by Universities/Institutes, H2 2016 20
Diabetic Neuropathy - Pipeline by Achelios Therapeutics, Inc., H2 2016 21
Diabetic Neuropathy - Pipeline by Araim Pharmaceuticals, Inc., H2 2016 22
Diabetic Neuropathy - Pipeline by Celgene Corporation, H2 2016 23
Diabetic Neuropathy - Pipeline by Commence Bio, Inc., H2 2016 24
Diabetic Neuropathy - Pipeline by Glucox Biotech AB, H2 2016 25
Diabetic Neuropathy - Pipeline by KPI Therapeutics, Inc., H2 2016 26
Diabetic Neuropathy - Pipeline by Lpath, Inc., H2 2016 27
Diabetic Neuropathy - Pipeline by Medifron DBT Co., Ltd., H2 2016 28
Diabetic Neuropathy - Pipeline by Neuralstem, Inc., H2 2016 29
Diabetic Neuropathy - Pipeline by NovaLead Pharma Pvt. Ltd., H2 2016 30
Diabetic Neuropathy - Pipeline by Novartis AG, H2 2016 31
Diabetic Neuropathy - Pipeline by Omeros Corporation, H2 2016 32
Diabetic Neuropathy - Pipeline by PhiloGene, Inc., H2 2016 33
Diabetic Neuropathy - Pipeline by Reata Pharmaceuticals, Inc., H2 2016 34
Diabetic Neuropathy - Pipeline by Relief Therapeutics S.A., H2 2016 35
Diabetic Neuropathy - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 36
Diabetic Neuropathy - Pipeline by ViroMed Co Ltd, H2 2016 37
Assessment by Monotherapy Products, H2 2016 38
Number of Products by Stage and Target, H2 2016 40
Number of Products by Stage and Mechanism of Action, H2 2016 43
Number of Products by Stage and Route of Administration, H2 2016 46
Number of Products by Stage and Molecule Type, H2 2016 48
Diabetic Neuropathy - Dormant Projects, H2 2016 106
Diabetic Neuropathy - Dormant Projects (Contd..1), H2 2016 107
Diabetic Neuropathy - Dormant Projects (Contd..2), H2 2016 108
Diabetic Neuropathy - Dormant Projects (Contd..3), H2 2016 109
Diabetic Neuropathy - Discontinued Products, H2 2016 110

List of Figures
Number of Products under Development for Diabetic Neuropathy, H2 2016 10
Number of Products under Development for Diabetic Neuropathy - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Products, H2 2016 17
Assessment by Monotherapy Products, H2 2016 38
Number of Products by Top 10 Targets, H2 2016 39
Number of Products by Stage and Top 10 Targets, H2 2016 39
Number of Products by Top 10 Mechanism of Actions, H2 2016 42
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 42
Number of Products by Routes of Administration, H2 2016 45
Number of Products by Stage and Routes of Administration, H2 2016 45
Number of Products by Molecule Types, H2 2016 47
Number of Products by Stage and Molecule Types, H2 2016 47

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *